ALS stem cell study halted after just one patient

NCT ID NCT06910384

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single dose of STR04, made from a patient's own bone marrow stem cells, for amyotrophic lateral sclerosis (ALS). Only one person enrolled before the study was stopped early. The goal was to see if the treatment was safe and could slow the disease, but no conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

autologous bone-marrow-derived mesenchymal stem cells

What this could lead to

If successful, this approach could point toward a treatment to slow ALS progression.

What could go wrong

The trial was terminated early with only 1 participant, so results are not reliable. Stem cell treatments for ALS remain unproven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Neuromuscular Research Institute

    Austin, Texas, 78759, United States